BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was downgraded by investment analysts at Barclays PLC from an “overweight” rating to an “equal weight” rating in a research report issued to clients and investors on Tuesday. They currently have a $105.00 target price on the stock, down from their previous target price of $125.00. Barclays PLC’s price objective would suggest a potential upside of 22.62% from the stock’s current price.

Several other research analysts also recently commented on BMRN. Vetr downgraded shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating and set a $103.86 price objective for the company. in a report on Monday, August 1st. Stifel Nicolaus raised their price target on shares of BioMarin Pharmaceutical from $107.00 to $113.00 and gave the company a “buy” rating in a report on Friday, August 5th. Piper Jaffray Cos. raised their price target on shares of BioMarin Pharmaceutical from $107.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, August 5th. Jefferies Group raised their price target on shares of BioMarin Pharmaceutical from $116.00 to $120.00 and gave the company a “buy” rating in a report on Friday, August 5th. Finally, JPMorgan Chase & Co. raised their price target on shares of BioMarin Pharmaceutical from $120.00 to $127.00 and gave the company an “overweight” rating in a report on Friday, August 5th. Six analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $114.35.

Analyst Recommendations for BioMarin Pharmaceutical (NASDAQ:BMRN)

Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) opened at 85.63 on Tuesday. The firm’s market capitalization is $14.73 billion. BioMarin Pharmaceutical has a 12-month low of $62.12 and a 12-month high of $107.56. The company has a 50-day moving average price of $86.14 and a 200-day moving average price of $89.66.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, October 27th. The company reported ($0.26) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.13. The company earned $279.90 million during the quarter, compared to the consensus estimate of $289.70 million. BioMarin Pharmaceutical had a negative net margin of 46.22% and a negative return on equity of 8.54%. BioMarin Pharmaceutical’s revenue for the quarter was up 34.0% on a year-over-year basis. During the same period last year, the firm earned ($0.60) EPS. Equities analysts predict that BioMarin Pharmaceutical will post ($3.73) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “BioMarin Pharmaceutical Inc. (BMRN) Rating Lowered to Equal Weight at Barclays PLC” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was copied illegally and republished in violation of international copyright law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/12/01/biomarin-pharmaceutical-inc-bmrn-rating-lowered-to-equal-weight-at-barclays-plc.html.

In related news, EVP Jeffrey Robert Ajer sold 18,467 shares of the business’s stock in a transaction dated Tuesday, September 27th. The shares were sold at an average price of $95.61, for a total transaction of $1,765,629.87. Following the sale, the executive vice president now owns 41,342 shares of the company’s stock, valued at $3,952,708.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jean Jacques Bienaime sold 137,368 shares of the business’s stock in a transaction dated Friday, September 16th. The stock was sold at an average price of $95.34, for a total transaction of $13,096,665.12. Following the sale, the chief executive officer now directly owns 421,161 shares in the company, valued at approximately $40,153,489.74. The disclosure for this sale can be found here. Insiders own 2.50% of the company’s stock.

A number of large investors have recently bought and sold shares of BMRN. Parametrica Management Ltd raised its stake in BioMarin Pharmaceutical by 149.4% in the second quarter. Parametrica Management Ltd now owns 6,507 shares of the company’s stock valued at $506,000 after buying an additional 3,898 shares during the last quarter. LS Investment Advisors LLC raised its stake in BioMarin Pharmaceutical by 13.5% in the second quarter. LS Investment Advisors LLC now owns 1,946 shares of the company’s stock valued at $151,000 after buying an additional 231 shares during the last quarter. IBM Retirement Fund raised its stake in BioMarin Pharmaceutical by 1.8% in the second quarter. IBM Retirement Fund now owns 19,233 shares of the company’s stock valued at $1,562,000 after buying an additional 346 shares during the last quarter. Hartford Investment Management Co. raised its stake in BioMarin Pharmaceutical by 2.5% in the second quarter. Hartford Investment Management Co. now owns 2,906 shares of the company’s stock valued at $226,000 after buying an additional 70 shares during the last quarter. Finally, Rockefeller Financial Services Inc. acquired a new stake in BioMarin Pharmaceutical during the second quarter valued at approximately $111,000. 97.54% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

5 Day Chart for NASDAQ:BMRN

Receive News & Stock Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.